Savara (NASDAQ:SVRA) Given New $10.00 Price Target at HC Wainwright

Savara (NASDAQ:SVRA) had its price target raised by HC Wainwright from $6.00 to $10.00 in a report released on Thursday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities analysts have also issued reports on SVRA. Evercore ISI reduced their price target on Savara from $10.00 to $7.00 and set an outperform rating on the stock in a research report on Thursday, May 16th. Piper Sandler increased their price target on shares of Savara from $7.00 to $16.00 and gave the company an overweight rating in a research report on Monday, March 4th. JMP Securities restated a market outperform rating and issued a $8.00 price objective on shares of Savara in a research report on Monday, May 6th. Finally, Oppenheimer increased their target price on shares of Savara from $11.00 to $15.00 and gave the stock an outperform rating in a report on Wednesday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Savara has an average rating of Buy and an average price target of $11.00.

Savara Stock Down 0.8 %

Shares of NASDAQ SVRA opened at $3.81 on Thursday. The stock has a market capitalization of $526.50 million, a P/E ratio of -10.30 and a beta of 0.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.90 and a quick ratio of 14.90. Savara has a one year low of $2.63 and a one year high of $5.70. The firm’s 50 day simple moving average is $4.32 and its two-hundred day simple moving average is $4.63.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, analysts expect that Savara will post -0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

Several institutional investors and hedge funds have recently modified their holdings of SVRA. ProShare Advisors LLC lifted its holdings in Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after buying an additional 2,114 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Savara by 15.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock valued at $168,000 after purchasing an additional 4,625 shares during the period. CANADA LIFE ASSURANCE Co bought a new stake in shares of Savara during the first quarter valued at approximately $35,000. AJOVista LLC purchased a new stake in Savara in the fourth quarter worth $40,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Savara by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock worth $130,000 after purchasing an additional 10,381 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.